TSL Thinksmart Limited

RNS Number:0807M
Tissue Science Laboratories PLC
10 May 2005



                                                                     10 May 2005

                        Tissue Science Laboratories plc
                            ('TSL' or 'the Company')

                         Permacol(R) Injectable Patent

Tissue Science Laboratories plc (LSE: TSL), the medical devices company
specialising in human tissue replacement and repair products derived from
porcine dermis, announced that its US patent application for composition of
matter for its injectable form of Permacol(R) has been allowed by the US Patent
and Trademark Office. It is anticipated that the patent will be granted at the
end of Q2 2005.

Permacol(R) Injection is indicated for use as a Urethral Bulking Agent (UBA) for
female urinary stress incontinence (FUSI). Stress incontinence is a common
condition affecting one in eight women over the age of 45 and, in the US alone,
there are an estimated 11 million sufferers. The Company's main focus is on the
US market where injectable bulking agents have been more widely adopted and
where the Company believes that its product would offer advantages over existing
treatments.

Permacol(R) Injection UBA is a natural product and therefore has none of the
safety concerns associated with synthetics and, as a one-off treatment, it
provides a long-lasting solution. Initial analysis of a double-blinded study
indicates that Permacol(R) Injection is an effective bulking agent for the
treatment of female stress incontinence. Once fully analysed and published, the
data will be used to support marketing in Europe, where the product is already
being sold.

Commenting on today's announcement, Martin Hunt, CEO of TSL, said:
"Achieving a patent for our injectable product is an important milestone for the
Company in the development of a strong intellectual property portfolio to
protect our products."
                                     -Ends-
Enquiries:

TSL plc                                             Tel: 01252 369603
Martin Hunt, Chief Executive

Hogarth Partnership Limited                         Tel: 020 7357 9477
Melanie Toyne-Sewell / Kate Catchpole               Mob: 07767 66 00 40

Notes to Editors

Background on TSL

Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product, derived from porcine dermis, called Permacol(R). TSL
has launched successfully different formulations of the product and built a
development pipeline that addresses the large and fast growing surgical implant
market.  The Company floated in November 2001 and is listed on the Alternative
Investment Market (LSE: TSL).

TSL has a family of products based on the same core technology.  Each product
has been adapted, with unique properties, to make it suitable for use in
different applications, including urology/gynaecology, complex and recurrent
hernia repair, shoulder rotator cuff repair and head and face repair and
reconstruction. The Company has signed distribution agreements with CR Bard Inc
(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) and
Porex Surgical Inc (head & face-US and Canada). Further variations of the sheet
and injectable forms of Permacol(R) are being developed.

Background on Permacol(R)
Permacol(R) was developed at Dundee University over a 20 year time period and
has been patented worldwide. The key to the Permacol(R) concept lies in its
collagen Technology which uses non-reconstituted porcine dermal collagen, very
similar in structure to human tissue. Non-collagenous material, except elastin,
is removed by the TSL manufacturing process. The remaining collagen, which
retains its original 3-D structural architecture, is stabilised by a patented
cross-linking process. The result is a non-reconstituted, non-allergenic,
collagen implant which is resistant to biodegradation attack, is recognised and
accepted by the body, and is able to provide a long-term support for the
in-growth of new tissue and its associated blood supply.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRSSSFUUSISESI

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024